Phosphoprotein associated with glycosphingolipid microdomains 1 inhibits the proliferation and invasion of human prostate cancer cells in vitro through suppression of Ras activation

Yu,Wenjuan; Wang,Yuewei; Gong,Miaozi; Pei,Fei; Zheng,Jie

doi:10.3892/or.2012.1848

Phosphoprotein associated with glycosphingolipid microdomains 1 inhibits the proliferation and invasion of human prostate cancer cells in vitro through suppression of Ras activation

Authors:
- Wenjuan Yu
- Yuewei Wang
- Miaozi Gong
- Fei Pei
- Jie Zheng
View Affiliations

Affiliations: Department of Pathology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, P.R. China, Department of Vascular Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, P.R. China, Department of Pathology, Health Science Center, Peking University, Beijing, P.R. China
Published online on: June 1, 2012 https://doi.org/10.3892/or.2012.1848
Pages: 606-614

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphoprotein associated with glycosphingolipid microdomains 1 (PAG) is an important negative regulator of immune signaling in T lymphocytes. However, newly emerging evidence has indicated that PAG may play important roles in tumor cells. Our previously reported cDNA microarray experiments identified PAG as a gene down-regulated in the high metastatic potential prostate cancer cell line PC-3M-1E8. In this study, we investigated the role of PAG in the proliferation, invasion and metastasis of prostate cancer cells and the underlying mechanisms. We confirmed that the expression of PAG at both the mRNA and protein levels was low in PC-3M-1E8 and DU145 cells compared to low metastatic potential prostate cancer cells PC-3M-2B4. In addition, we demonstrated that the reintroduction of PAG to PC-3M-1E8 and DU145 cells led to reduced proliferation through cell cycle arrest, decreased anchorage-independent growth and reduced invasion ability of tumor cells in vitro. This is the first report demonstrating that PAG inhibits the proliferation and invasion potential of prostate cancer cells via the interaction with RasGAP to recruit RasGAP to the cell membrane, where RasGAP hydrolyzes GTP to GDP, reduces the level of activated Ras, and ultimately suppresses the activation of ERK1/2, cyclin D1 and other effectors of the Ras signaling pathway. Morphologically, we observed that PAG could diminish the formation of pseudopodia on the cell surface and redistribute the intracellular F-actin in PC-3M-1E8 cells, which directly leads to the decreased invasion and metastasis potential of tumor cells. Taken together, these results suggest that PAG acts to inhibit the development and metastasis of prostate cancers and represents a novel therapeutic target for prostate cancer.

View Figures

View References

1	Liu YX, Zheng J and Fang WG: Isolation and characterization of human prostate cancer cell subclones with different metastatic potential. Chin J Pathol. 28:361–364. 1999.PubMed/NCBI
2	Svec A: Phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk-binding protein: a protein that matters. Pathol Res Pract. 204:785–792. 2008. View Article : Google Scholar
3	Brdickova N, Brdicka T, Andera L, Spicka J, Angelisova P, Milgram SL and Horejsi V: Interaction between two adapter proteins, PAG and EBP50: a possible link between membrane rafts and actin cytoskeleton. FEBS Lett. 507:133–136. 2001. View Article : Google Scholar
4	Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A and Okada M: Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 404:999–1003. 2000. View Article : Google Scholar : PubMed/NCBI
5	Takeuchi S, Takayama Y, Ogawa A, Tamura K and Okada M: Transmembrane phosphoprotein cbp positively regulates the activity of the carboxyl-terminal src kinase Csk. J Biol Chem. 275:29183–29186. 2000. View Article : Google Scholar : PubMed/NCBI
6	Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Hilgert I, Cerny J, Drbal K, Kuramitsu Y, Kornacker B, Horejsi V and Schraven B: Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med. 191:1591–1604. 2000. View Article : Google Scholar
7	Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, Schraven B, Rolstad B, Mustelin T and Tasken K: Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem. 276:29313–29318. 2001. View Article : Google Scholar
8	Jiang LQ, Feng X, Zhou W, Knyazev PG, Ullrich A and Chen Z: Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation. Oncogene. 25:5495–5506. 2006. View Article : Google Scholar
9	Smida M, Posevitz-Fejfar A, Horejsi V, Schraven B and Lindquist JA: A novel negative regulatory function of the phosphoprotein associated with glycosphingolipid-enriched microdomains: blocking Ras activation. Blood. 110:596–615. 2007. View Article : Google Scholar
10	Durrheim GA, Garnett D, Dennehy KM and Beyers AD: Thy-1 associated pp85–90 is a potential docking site for SH2 domain-containing signal transduction molecules. Cell Biol Int. 25:33–42. 2001.PubMed/NCBI
11	Sanchez-Margalet V and Najib S: Sam68 is a docking protein linking GAP and PI3K in insulin receptor signaling. Mol Cell Endocrinol. 183:113–121. 2001. View Article : Google Scholar : PubMed/NCBI
12	Huang KT, Chen YH and Walker AM: Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. Biotechniques. 37:406–412. 2004.PubMed/NCBI
13	Simeoni L, Smida M, Posevitz V, Schraven B and Lindquist JA: Right time, right place: the organization of membrane proximal signaling. Semin Immunol. 17:35–49. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cloutier JF, Chow LM and Veillette A: Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. Mol Cell Biol. 15:5937–5944. 1995.
15	Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, Nakajima N, Okada M and Saito T: Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J Immunol. 168:541–544. 2002. View Article : Google Scholar : PubMed/NCBI
16	Harder T and Simons K: Clusters of glycolipid and glycosylphosph atidylinositol-anchored proteins in lymphoid cells: accumulation of actin regulated by local tyrosine phosphorylation. Eur J Immunol. 29:556–562. 1999. View Article : Google Scholar
17	Condeelis JS, Wyckoff JB, Bailly M, Pestell R, Lawrence D, Backer J and Segall JE: Lamellipodia in invasion. Semin Cancer Biol. 11:119–128. 2001. View Article : Google Scholar : PubMed/NCBI